PLEKHH2

Across TCGA pan-cancer cohorts, PLEKHH2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHH2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLEKHH2 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated PLEKHH2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, STAD, and CESC are the cancer types where PLEKHH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.959	0.307	<.001	36	view →
STAD	DFS	Median	All	1.000	0.340	.008	29	view →
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
LUSC	DFS	Median	II,III,IV	0.139	0.663	.027	3	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHH2–UCEC (OS)

Open the UCEC breakdown →